Abbvie 3Q Results

Abbvie

3Q Revenues: $15.8 billion (+9%) 

3Q Earnings: $186 million (earnings were $1.6B 3Q24)

YTD Revenues: $44.5 billion (+8%)

YTD Earnings: $2.4 billion (-44%)

Comments: Global sales from the immunology portfolio were $7.9 billion, up 12%. Skyrizi sales were $4.7 billion, up 47%. Rinvoq sales were $2.2 billion, up 35%. Humira sales were $993 million, down 55%.

Global revenues from the oncology portfolio were flat at $1.7 billion. Imbruvica sales were $706 million, down 15%. Venclexta sales were $726 million, up 7%. Elahere sales were $170 million, up 23%.

Global revenues from the aesthetics portfolio were $1.2 billion, down 4%. Botox Cosmetic sales were $637 million, down 5%. Juvederm sales were $253 million, down 2%.